A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
about
Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteraturePersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineImpact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipientsAssociation of an NFKB1 intron SNP (rs4648068) with gastric cancer patients in the Han Chinese populationNovel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.PharmGKB summary: cyclosporine and tacrolimus pathwaysCYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohortErlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patientsMultigene predictors of tacrolimus exposure in kidney transplant recipients.Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritAssociation of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenParsing interindividual drug variability: an emerging role for systems pharmacology.Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemMultiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymesExternal evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Program in pharmacogenomics at the Ohio State University Medical Center.CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid controlCYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrationsInfluence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profileMultidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipientsA published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel responsePharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patientsThe Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Cytochrome P450 variations in different ethnic populations.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.Cytochrome P450 pharmacogenetics in African populations.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
P2860
Q28073025-C3FC67F8-EDFF-492B-8356-9B917696E59DQ28082746-B4F575A9-C2D4-4B6B-8C05-A92430A536F6Q28538933-370B4FAD-EB48-4BF6-8A75-2CF90C276FF1Q28728691-C3FEE242-2C45-4CF2-AD78-EE5B42E389D7Q31133709-3C1E28AE-A83F-4B99-80E7-FC05322AA29FQ33628473-BA29D867-846A-4B86-BAAC-2EF2EDE28ED2Q33989902-127D7FC2-E797-4AB1-8EED-EAE313C6C38EQ34160942-65449BCC-D7D9-4D99-B837-2CD2CC7B74EFQ34266864-49DBAB3A-2A36-4C6A-8084-A5811B917126Q34307589-5023D115-D87A-4C8E-A44F-C39E9A4E81C1Q35618156-6123FC58-6C4C-48C5-8E85-2CFD21FEE833Q35924246-0A377B9F-B1AB-4C39-92E1-41BF87CA853EQ36072508-AECCB2CE-97DA-425E-ACAD-D4C693F3BA22Q36275134-73A50068-C72C-46F4-B6DE-FBCDD1574762Q36322918-052009AE-A202-469F-8801-57A2A8013633Q36417380-198EB0FA-776D-42E6-A920-B3A132786293Q36465101-DA792FFA-597A-41B0-B360-9F8D107E6FF0Q36634077-A9A407BF-7CC4-40B0-8ED9-5D3F2835059CQ36650954-81655DDD-F7EC-4A75-AF71-946DAA33001DQ36750899-8819B20E-51C7-4E23-9F51-5CFE8444006FQ36776572-06BACEE1-C105-4E15-B789-C7468F78DA23Q36806621-18EF2B70-F399-48B2-AFF0-99D22C8261DEQ36833654-7721D46E-9592-4989-93A2-3BA24CB60C6AQ36927210-2ED9665C-D34D-4833-934F-D2019E2303A0Q36940993-0CDB0907-B438-410C-B548-DE6EBCC7C53CQ36948144-3BAF33F5-3420-442F-90C9-A657AA444585Q37063883-3644C577-4AD7-4396-B713-AFE9BE58DF05Q37126092-49BF78D2-07EF-4F64-B921-3F763D988888Q37161904-A031C5DA-0461-476D-BB42-393371B1DF95Q37390889-EB1BED15-3112-4C87-83A2-88FEBAB1E1CEQ37439873-BB1933F6-3016-4D2B-9250-69ED6F0581A8Q37513374-8C37D9FC-689A-44D9-BAFB-AEB50C1F69F7Q37608121-C045AA0B-AD9E-4E0A-904D-CF7245F2A37BQ37620393-B06A3404-DC2B-4637-B5DD-A80BBFEC9243Q37678060-13CCED94-D8A5-4E21-BCB7-BD44321F5D60Q37979866-6CB8C0DD-FDC7-4E97-9547-2827465AFC0EQ38063426-E659CE32-F820-4BBE-97D7-47BEE9330292Q38068539-FB97E65A-9AB9-4E1E-97C2-0FCDE2A87A88Q38099372-BE7B8F20-5D2E-4771-B31B-7B2466B3FFCEQ38163945-50EE0949-B58E-4996-8680-4BDDFDE45BDA
P2860
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A new functional CYP3A4 intron ...... kidney transplant recipients.
@en
A new functional CYP3A4 intron ...... kidney transplant recipients.
@nl
type
label
A new functional CYP3A4 intron ...... kidney transplant recipients.
@en
A new functional CYP3A4 intron ...... kidney transplant recipients.
@nl
prefLabel
A new functional CYP3A4 intron ...... kidney transplant recipients.
@en
A new functional CYP3A4 intron ...... kidney transplant recipients.
@nl
P2093
P1433
P1476
A new functional CYP3A4 intron ...... n kidney transplant recipients
@en
P2093
Dennis A Hesselink
Ilse P van der Heiden
Rachida Bouamar
Ron H N van Schaik
Teun van Gelder
Vincent Haufroid
P304
P356
10.1373/CLINCHEM.2011.165613
P407
P50
P577
2011-09-08T00:00:00Z